Health Economics›Myelodysplastic syndrome›Lower-risk MDS all lines of therapy

Lower-risk MDS all lines of therapy

Myelodysplastic syndrome · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~39.0 mo	~113.8 mo	~14	~R 89 057 PFS proxy · indirect	10
Erythropoetin beta and Lenalidomide Variant #01	—	R 1 089	28d	—	—	—	—	—
Erythropoetin alfa and Lenalidomide Variant #01	—	R 726	7d	—	—	—	—	—
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145
Erythropoietin alfa monotherapy Variant #01 Partial	—	—	7d	—	—	—	—	—
Luspatercept monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Azacitidine oral monotherapy Variant #01 Partial	—	—	28d	—	~24.7 mo	—	—	—
Darbepoetin alfa monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—

8 of 8 regimens shown